Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11525254 | 0.98 | MEN1 (0.40) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL21801417 | 0.92 | SMN1; SMN2 (0.40) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL2788345 | 0.84 | CHRNB2 (0.33) | CYP2D6ALDH1A1 | |
| SCHEMBL17629524 | 0.84 | CHRNB2 (0.33) | CYP2D6ALDH1A1 | |
| SCHEMBL28634630 | 0.78 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL3905171 | 0.78 | SMN1; SMN2 (0.38) | CYP2D6 | |
| SCHEMBL688825 | 0.78 | SMN1; SMN2 (0.38) | CYP2D6 | |
| SCHEMBL688697 | 0.78 | SMN1; SMN2 (0.38) | CYP2D6 | |
| SCHEMBL8704065 | 0.76 | SMN1; SMN2 (0.37) | CYP2D6 | |
| SCHEMBL8682105 | 0.73 | CHRM1 (0.44) | CHRM1CYP2D6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3553083-B2 | — | — | 2004-08-11 | — | — | JP | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| CN-103459388-B | Novel furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2015-11-25 | — | — | CN | disclosed |
| CN-103459388-A | Novel furanone derivative | SBI BIOTECH CO LTD | 2013-12-18 | — | — | CN | disclosed |
| CN-101128456-B | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB | 2013-01-23 | — | — | CN | disclosed |
| CN-101128456-A | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
| US-6608078-B2 | Gramnegative bacteria | WOCKHARDT LIMITED (IN) | 2003-08-19 | — | — | US | disclosed |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | WOCKHARDT RESEARCH CENTER | 2002-11-07 | — | — | US | disclosed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001085728-A2 | ANTIBACTERIAL CHIRAL 8-(SUBSTITUTED PIPERIDINO)-BENZO [I, J] QUINOLIZINES, PROCESSES, COMPOSITIONS AND METHODS OF TREATMENT | WOCKHARDT LIMITED (IN) | 2001-11-15 | — | — | WO | disclosed |
| CN-1031376-A | Pyrazolopyridine compound and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1989-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | ALPI, POLR1C, POLI | CHRM2 3743/4885CHRM1 2151/4885MEN1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.